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Laplace’s law, which can be used to estimate myocardial wall stress() from intraventricular pressure (LVP), radius of curvature (R),and wall thickness (h), has long been recognized as a fundamentalphysical principle in understanding cardiac function in health anddisease:   LVP  R/h. On the basis of this law, the enlargedchamber radius of the chronically failing heart exposes myocytes to
increased systolic wall stress. This leads to cellular and chamber hypertrophy,
which, in an adaptive process, acts to renormalize wall stress.1 As the chamber
continues to dilate over time, the limits of hypertrophy appear to be reached so that
wall stress ultimately increases. This increased afterload further impairs the ability
of the already weakened myocytes to shorten, and cardiac performance deteriorates.
Globally referred to as ventricular remodeling, this process is partially preventable
and reversible as demonstrated in studies of angiotensin-converting enzyme inhib-
itors,2 -blockers,3 and during hemodynamic unloading by prolonged support with
a left ventricular assist device.4
Several surgical therapies, such as the Myocor ventricular shape change device
(Myocor, Inc, Plymouth, Minn), described in this issue by McCarthy and col-
leagues,5 are being developed for treating heart failure by physically remodeling the
dilated heart. Stress reduction via Laplace’s law is usually sited as the rationale for
these therapies. The Batista procedure6 (partial left ventriculectomy for patients with
idiopathic cardiomyopathy) is an important predicate example. Despite initial en-
thusiasm, clinical studies showed that although estimated wall stress was reduced,
a majority of patients did not experience improved hemodynamics or clinical status
in the long term.7 In my opinion, one limitation in thinking about this procedure was
the focus on its potentially beneficial effects on wall stress to the exclusion of
considering its effects on overall pump function. Specifically, the effects of myo-
cardial resection on diastolic ventricular properties were under-appreciated. When
expressed in terms of end-systolic and end-diastolic pressure-volume relationships
(ESPVR and EDPVR, respectively), theory predicted8,9 and clinical research later
showed10 that despite the potentially beneficial effects on systolic properties of
shifting the ESPVR leftward (increased chamber contractility), the Batista proce-
dure was also associated with counteracting effects on diastole. These were manifest
as similar, or even greater, leftward shifts of the EDPVR with a net result of little
net benefit on overall left ventricular pumping capacity (Figure 1, A). Hypotheti-
cally, it would be more desirable for a therapy to cause a larger leftward shift in the
ESPVR than in the EDPVR (Figure 1, B), which would result in a greater
ventricular pumping capacity. Furthermore, we argued that changes in ejection
fraction resulting from reductions in end-diastolic volume without changes in stroke
volume are not indicative of improved systolic function as they are in the setting of
standard inotropic therapy.8
McCarthy and colleagues, who played a pivotal role in the systematic clinical
evaluation of the Batista operation,11 have not abandoned the concept that radius of
curvature reduction can have a favorable impact on ventricular function. The
investigators used struts (Myosplint; Myocor, Inc) placed across the ventricle to pull
opposing sides of the chamber together to alter ventricular shape and functionally
separate the chamber into two lobes, each with a smaller radius than the original
heart.5 An easy to understand explanation of how Laplace’s law predicts systolic
wall stress reduction by this shape change therapy is provided by the authors. This
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concept is also supported by more sophisticated computa-
tional model analysis of the same concept performed by
other investigators.12
Experimentally, McCarthy and associates show that, as
intended, the Myosplint device reduces ventricular end-
diastolic volume, end-systolic volume, and wall stress while
increasing ejection fraction; these effects are sustained to
the maximum time investigated, 1 month. However, there
were no significant changes in cardiac output, end-diastolic
pressure, or mean arterial pressure. These data indicate that
there are leftward shifts (smaller volumes at similar pres-
sures) in both ESPVR and EDPVR and furthermore suggest
that the shifts of these relationships are likely to be rela-
tively balanced so that there is little net effect on overall
pump function (as in Figure 1, A). With no acute or possibly
even chronic hemodynamic benefit, pivotal questions in-
clude whether the Myosplint device actually resulted in
regression of hypertrophy (wall thickness and heart mass
data would be of interest) and whether any such changes
would translate into clinically meaningful effects on patient
Figure 1. Ventricular pump properties are typically represented by ESPVR and EDPVR. In heart failure (red) both
systolic and diastolic curves are shifted toward significantly larger volumes compared with normal (gray), a
manifestation of ventricular remodeling. It was shown previously that with the Batista procedure (blue), and
possibly for the Myosplint device, there is a rightward shift of the EDPVR that is slightly greater than the shift in
the ESPVR (A), resulting in little change in net ventricular pump function as shown by the pressure-volume loops
with similar stroke volumes at comparable end-diastolic and aortic pressures. This would contrast with a
hypothetical therapy that would induce a greater leftward shift of the ESPVR than EDPVR and cause an increase
in net pumping capacity (B), as shown by the pressure-volume loop (blue), with significantly increased stroke
volume compared with the heart failure state (red) at comparable end-diastolic and aortic pressures.
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symptoms, disease progression, and/or mortality. The latter
are difficult issues to address in preclinical studies.
As noted above, several forms of surgical therapies are
being investigated to physically remodel the failing heart,
including other passive devices13 and resection of akinetic
scars.14 There is a need to better define the effects of such
procedures on a broad range of mechanical and biochemical
properties of the heart; consideration of effects on wall
stress alone may not reveal the entire picture. The impor-
tance of improved understanding stems at least in part from
the need for physicians considering referring their patients
for clinical trials to be able to assess the potential that a
surgical heart failure therapy with little (if any) acute he-
modynamic benefits will ultimately translate into clinical
benefits. Could this be the case for a therapy that changes
the shape of the failing heart? If such benefits were con-
firmed by careful clinical investigation, surgeons could have
a means of meaningfully affecting the heart failure epidemic
and change the shape of heart failure treatment in the future.
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